Draft Guidance on Ranitidine Hydrochloride

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Ranitidine hydrochloride

Dosage Form; Route: Capsule; oral

Recommended Studies: Two studies

1. Type of study: Fasting
   Design: Single-dose, two-way crossover in vivo
   Strength: EQ 300 mg base
   Subjects: Healthy males and nonpregnant females, general population
   Additional comments: Females should not be pregnant or lactating, and, if applicable, should practice abstention or contraception during the study.

2. Type of study: Fed
   Design: Single-dose, two-way crossover in vivo
   Strength: EQ 300 mg base
   Subjects: Healthy males and nonpregnant females, general population
   Additional comments: See comments above.

Analytes to measure (in appropriate biological fluid): Ranitidine in plasma

Bioequivalence based on (90% CI): Ranitidine

Waiver request of in vivo testing: EQ 150 mg base strength based on (i) acceptable bioequivalence studies on the 300 mg strength, (ii) proportional similarity of the formulations across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths.

Dissolution test method and sampling times: The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods website available to the public at the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/.

Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application (ANDA).